ADVANCE Phase 3 research confirms clinical great things about telaprevir regimen in individuals with HCV infection The Phase 3 results from the ADVANCE study confirm the clinical great things about telaprevir-based combination therapy regimens. An improvement is reported by The study in treatment discontinuation prices due to adverse events compared to Phase 2 studies, and demonstrates a rise in sustained viral response in individuals with hepatitis C virus . The primary endpoint for this study was SVR 24 weeks after last treatment read more here . The scholarly research was conducted on 1088 treatment-naive HCV patients, all of whom got genotype 1. For the three arms of the trial, one group of individuals was treated with 750 mg of telaprevir every eight hours in combination with peginterferon alfa-2a 180 ug/week and ribavirin 1000-1200 mg/time for 12 weeks, as the second group was presented with the same treatment but for only eight weeks.